Author Archives: Gastroenterology Journal
Substantial variability in placebo and nocebo responses challenges the validity of network meta-analysis of gastroparesis pharmacotherapy
Posted in News
Comments Off on Substantial variability in placebo and nocebo responses challenges the validity of network meta-analysis of gastroparesis pharmacotherapy
Cold Snare Polypectomy for Small Colorectal Polyps – Quick and Safe
Posted in News
Comments Off on Cold Snare Polypectomy for Small Colorectal Polyps – Quick and Safe
Elevated APE1 dysregulates homologous recombination and cell cycle driving genomic evolution, tumorigenesis and chemoresistance in esophageal adenocarcinoma
Purpose of this study was to identify drivers of genomic evolution in esophageal adenocarcinoma (EAC) and other solid tumors. Continue reading
Posted in News
Comments Off on Elevated APE1 dysregulates homologous recombination and cell cycle driving genomic evolution, tumorigenesis and chemoresistance in esophageal adenocarcinoma
Discovery and Initial Characterization of Long Intergenic Non-coding RNAs Associated with Esophageal Adenocarcinoma
Posted in News
Comments Off on Discovery and Initial Characterization of Long Intergenic Non-coding RNAs Associated with Esophageal Adenocarcinoma
Bulevirtide for chronic Hepatitis Delta
Posted in News
Comments Off on Bulevirtide for chronic Hepatitis Delta
Enterochromaffin cells: small in number but big in impact.
Posted in News
Comments Off on Enterochromaffin cells: small in number but big in impact.
Gastro Curbside Consults: Not just another ‘bloody’ case of right heart failure
Posted in News
Comments Off on Gastro Curbside Consults: Not just another ‘bloody’ case of right heart failure
Sometimes gut smooth muscle forget that they are supposed to contract: CARMN and visceral myopathy
Posted in News
Comments Off on Sometimes gut smooth muscle forget that they are supposed to contract: CARMN and visceral myopathy
ALKBH5 Drives Immune Suppression via targeting AXIN2 to Promote Colorectal Cancer and is a Target for Boosting Immunotherapy
Immune checkpoint blockade (ICB) therapy only benefits a small subset of colorectal cancer (CRC) patients and identification of CRC-intrinsic events modulating ICB efficacy is an unmet need. Here, we revealed AlkB Homolog 5 (ALKBH5), an RNA N6-methylad… Continue reading
Posted in News
Comments Off on ALKBH5 Drives Immune Suppression via targeting AXIN2 to Promote Colorectal Cancer and is a Target for Boosting Immunotherapy